共 38 条
- [21] Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary MyelofibrosisBLOOD, 2010, 116 (21) : 1271 - 1271Verstovsek, SrdanDeeg, H. JoachimOdenike, OlatoyosiZhu, JoyKantarjian, HagopEstrov, ZeevScott, Bart LeeThomas, Deborah A.
- [22] Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with MyelofibrosisBLOOD, 2014, 124 (21)Mascarenhas, John O.Talpaz, MosheGupta, VikasFoltz, Lynda M.Savona, Michael R.Paquette, RonTurner, RobertCoughlin, PaulWinton, ElliottHunter, DeborahAssad, AlbertClark, JasonO'Neill, PeterHoffman, RonaldVerstovsek, Srdan
- [23] 24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITISRHEUMATOLOGY, 2013, 52 : 44 - 45Taylor, PeterGenovese, MarkKeystone, Edward C.Drescher, EditBerclaz, Pierre-YvesLee, ChinFidelus-Gort, RosalindSchlichting, DouglasBeattie, ScottLuchi, MonicaMacias, William
- [24] Trial in Progress: A Phase I/II Study of the JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow FailureBLOOD, 2024, 144Groarke, Emma M.Lotter, JenniferDarden, IvanaBikineyeva, AlfiyaOkeke, UzoamakaBlair, RachelErb-Alvarez, JulieChen, JichunFeng, XingminDurrani, JibranYoung, Neal S.Patel, Bhavisha A.
- [25] 12-Week Results Of a Phase 2b Dose-Ranging Study Of Baricitinib, An Oral JAK1/ JAK2 Inhibitor In Japanese Patients With Rheumatoid Arthritis On Background Methotrexate TherapyARTHRITIS AND RHEUMATISM, 2013, 65 : S765 - S765Tanaka, YoshiyaEmoto, KahakuTsujimoto, MikaSchlichting, Douglas E.Macias, William
- [26] Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancerCancer Chemotherapy and Pharmacology, 2021, 87 : 673 - 679Filipa LynceJames T. WilliamsMeredith M. ReganCraig A. BunnellRachel A. FreedmanSara M. TolaneyWendy Y. ChenErica L. MayerAnn H. PartridgeEric P. WinerBeth Overmoyer
- [27] Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancerCANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (05) : 673 - 679Lynce, FilipaWilliams, James T.Regan, Meredith M.Bunnell, Craig A.Freedman, Rachel A.Tolaney, Sara M.Chen, Wendy Y.Mayer, Erica L.Partridge, Ann H.Winer, Eric P.Overmoyer, Beth
- [28] A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter StudyBLOOD, 2024, 144 : 1808 - 1809Zhou, YileHuang, JianWen, BingbingZhou, HuYang, WeiFan, LianlianGong, TiejunGao, SujunJiao, ZongjiuLiu, QingchiZhao, LidongWu, GuocaiWu, CuicuiWang, JunZhang, JinFu, JiapingSheng, ZengmeiZhu, ZunminLu, JianZhang, YiJin, Jie
- [29] Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MFBLOOD, 2011, 118 (21) : 1642 - 1643Mesa, Ruben A.Gotlib, JasonGupta, VikasDiPersio, John F.Catalano, JohnDeininger, Michael W.Shields, AlanMiller, Carole B.Silver, Richard T.Talpaz, MosheWinton, Elliott F.Harvey, Jimmie H., Jr.Hare, ThomasErickson-Viitanen, SueSun, WilliamSandor, Victor A.Levy, Richard S.Kantarjian, Hagop M.Verstovsek, Srdan
- [30] 12-WEEK RESULTS OF A PHASE 2B DOSE-RANGING STUDY OF LY3009104 (INCB028050), AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITISANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 152 - 153Keystone, E.Taylor, P.Genovese, M.Schlichting, D.Beattie, S.Gaich, C.Gort, R. FidelusLuchi, M.Macias, W. L.